Skip to main content
. 2022 Jun 23;14(7):1372. doi: 10.3390/v14071372

Figure 8.

Figure 8

Proliferation response of HPV+ CU-OP-2, CU-OP-3, CU-OP-20, and HPV− CU-OP-17 cell lines upon combined treatment with PD-0332991 and BYL719 or JNJ-42756493. Proliferation responses of HPV+ CU-OP-2, CU-OP-3, CU-OP-20, and HPV− CU-OP-17 after treatment with CDK4/6 inhibitor PD-0332991 and PI3K inhibitor BYL719 (A–D) or with FGFR inhibitor JNJ-42756493 (E–H), or with the PARP inhibitor BMN-673 and WEE1 inhibitor MK-1775 (I–L). The graphs represent one experimental run per cell line. Confluence (%) denotes proliferation response; PD denotes PD-033299; BYL denotes BYL719; JNJ denotes JNJ-4275649; BMN denotes BMN-673; and MK denotes MK-1775.